Covidien Ltd.

The use of contrast media in many imaging modalities continues to evolve as physicians seek to improve dose management practices and vendors churn out automated injectors that can precisely control the amount of contrast and personalize doses for patients using information pulled from an electronic medical record (EMR) or picture archiving and communication system (PACS). The features of today’s contrast media injectors include syringeless options and dose recording software, offering new possibilities for radiology departments looking to streamline and document their contrast media usage.

Two next-generation automated contrast injector systems were recently introduced in the United States. 

February 17, 2010 — An agreement has been reached to further augment and diversify a manufacturer's supply of molybdenum 99 (Mo 99) to produce the medical isotope technetium 99m (Tc 99m).

November 10, 2009 – Covidien said yesterday it will voluntarily contraindicate the use of its Optimark gadoversetamide injection, a gadolinium-based contrast agent (GBCA), in magnetic resonance imaging (MRI) procedures involving patients with severe renal impairment.

June 16, 2009 - In response to the molybdenum 99 (Mo-99) supply shortage, Covidien sent out a letter to its customers informing them of the anticipated Covidien generator and unit dose (UD) Tc 99m supply to the overall U.S., Canadian and Latin American markets through August 2009.